TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change of Resilience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of composite complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in serum melatonin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Paris Functional Coccydynia Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Microbiome Diversity and Abundance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: SAB relapse microbiologically confirmed
Endpoint domain: Adverse events/effects
Primary endpoint: Progression-free Survival (PFS) status at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Accuracy of device to detect fiber intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Immune Checkpoint Inhibitor Treatment-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Metabolic pulmonary activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Somatic Symptom Score-8 (SSS-8)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time spent of glucose levels < 4.0 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of subjects experienced limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric mean titers of SARS-CoV-2 neutralizing antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Participants requiring mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Participants with all cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Late gadolinium enhancement/Left ventricular mass (LGE/LV%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Serious Safety Events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical characteristics of patients with Covid-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean NRS-S scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracranial Disease control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinical Status at Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pro BNP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Milk related symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Time-Activity Curves for Brain up to 90 Minutes (AUCbrain 0-90 min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under the Blood Concentrations Over Time for [11C]-Lu AF90103 and Radioactive Metabolites up to 90 Minutes (AUCblood 0-90 min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentrations Over Time for [11C]-Lu AF90103 and Radioactive Metabolites up to 90 Minutes (AUCplasma 0-90 min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal-infant health outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects who Achieve Glycosylated Hemoglobin (HbA1c) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Random Glucose Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment Emergent Adverse Effects
Endpoint domain: Adverse events/effects
Primary endpoint: rate of canine retraction distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NLRP3 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: target volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bray-curtis dissimilarity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differential abundance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excessive daytime sleepiness (EDS) after 3 months
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Excessive daytime sleepiness (EDS) after 6 months
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: European Quality of Life 5 dimensions Index (EQ 5D Index)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of cases with H.pylori infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area under the concentration-time curve of the analyte in plasma (AUC 0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of ENX-102 in reducing anxiety symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Aβ level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the Widespread Pain Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Responder Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Ferritin (ug/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Soluble Transferrin Receptor (mg/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Transferrin saturation (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hemoglobin (g/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in apnea hypopnea index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in obstructive apnea hypopnea index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in oxygen desaturation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in percent time with oxygen saturation less than 90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Falls risk assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute cerebrovascular accident
Endpoint domain: Mortality/survival
Primary endpoint: Neurological Sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Absence of pain to the evaporative stimulus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caring Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Electrophysiological markers of brain activity during sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Performance change in behavioral/cognitive tasks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in outcomes of subjective measures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: KAP score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of participants completed the intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Satisfaction with the treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of chemotherapy-related cognitive impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number and frequency of adverse events (AEs)/serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Namuscla treatment on the clinical outcomes based on the mean change in Visual Analogue Scale (VAS) for muscle stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulatory disturbance prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with grade 3 or 4 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Magnitude and duration of CAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Trail Making Test Black & White Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Increase in intra abdominal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction in pain level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Device safety (rate of adverse events and device related adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Inclusion criteria for hemoperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery after total hip arthroplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Kessler Psychological Distress Scale (K10)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of children on obesity trajectory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Daily pain score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Proportion of subjects reaching a histological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in dysphagia symptoms consistent with the disease
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ACL Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: hot flash symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of developing HPV-induced lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in hand use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gross motor performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of virtual reality sickness symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Usability of the virtual reality intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: proportion of patients with druggable molecular characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operational feasibility of visual assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intermittent hypoxemia event duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesions recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to initial meaningful clinical improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of clinically significant changes in electrocardiogram (ECG) results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence in clinically significant changes in vital sign measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of clinically significant changes in physical and neurological examination results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: changes in heart rate (HR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in blood pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ECG interval changes above a specific level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: proportion of patients who convert to SR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative number of alcohol standard drinks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Neoadjuvant Response (NAR) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Word recognition score (WRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Absence of electrographic evidence of status epilepticus or recurrence of convulsions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Natural History of 5q-SMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Utilization of Disease Modifying Therapies (DMTs)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of aortic-relative events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Parental Perceived Stress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Parental emotional functioning (ANXIETY)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parental emotional functioning (DEPRESSION)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parental Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CPOT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OA symptom severity (pain, stiffness and function)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in re-admission rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Respiratory muscles Strength Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postoperative pancreatic fistula (grade B+C)
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerance to supine position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Moderate to Vigorous Physical Activity (MVPA)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change on Perceived Muscle Soreness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of tablet interaction
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Acceptability of participation
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Rate of incidental pulmonary embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Related therapeutic consequences
Endpoint domain: Adverse events/effects
Primary endpoint: Immune changes in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change in serum free carnitine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in cardiac functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in Body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of severe SARS
Endpoint domain: Mortality/survival
Primary endpoint: MIP and MEP value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: pectoralis minor muscle length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Blood Pressure in mm/Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulse in beats/min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Respiratory Rate in breaths per minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Body Temperature in degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrocardiogram (ECG) as measured by PR interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: counts of each cell type
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mindful Attention Awareness Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cognitive Emotion Regulation Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: wound volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discomfort and pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Care Efficiency score
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Daily Skin Health score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline Repetition Maximum at 5 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline Hand Grip at 5 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline Lower-limb muscle strength at 5 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Complete ST-Segment Resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major Vascular Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in serum cortisol with oral estrogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in serum cortisol with transdermal estrogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Compassion fatigue
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Amount of Postpartum Hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Conjunctival composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically driven target lesion revascularization (CD-TLR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: patency rate of target (Femoropopliteal) lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportion of subjects with Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: satisfactory active ROM (flexion and extension)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in percent liver fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Non union scoring system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Karlström-Olerud physical function scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in LARS Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Thrombin generation parameter in PRP (Peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombin generation parameter in PRP (ETP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombin generation parameter in PRP (LT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: esophageal clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prognostic capacity of initial metabolomic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Beck Depression Inventory (BDI) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in the Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in 15D scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: British Picture Vocabulary Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Neck pain disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Successful ERCP Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ACT measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PROMIS Pain Interference
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PROMIS Self Efficacy for Managing Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ipsilateral new ischemic lesions on DWI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: FDG uptake (SUVmean, max, min, peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year disease progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: sustained virologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes